Courier Capital LLC Buys 166 Shares of Becton, Dickinson and Company $BDX

Courier Capital LLC increased its stake in Becton, Dickinson and Company (NYSE:BDXFree Report) by 3.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,355 shares of the medical instruments supplier’s stock after buying an additional 166 shares during the period. Courier Capital LLC’s holdings in Becton, Dickinson and Company were worth $922,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Northcape Wealth Management LLC raised its stake in Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock worth $2,248,000 after buying an additional 51 shares in the last quarter. Brady Family Wealth LLC increased its stake in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after purchasing an additional 53 shares in the last quarter. Diversified Trust Co increased its stake in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 53 shares in the last quarter. Bill Few Associates Inc. increased its stake in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after purchasing an additional 55 shares in the last quarter. Finally, Horizon Bancorp Inc. IN increased its stake in shares of Becton, Dickinson and Company by 10.9% during the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 56 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on BDX shares. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $205.40.

View Our Latest Report on Becton, Dickinson and Company

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock worth $562,036 over the last quarter. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.9%

Shares of BDX stock opened at $188.31 on Wednesday. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm’s 50 day moving average is $190.46 and its 200 day moving average is $185.47. The stock has a market capitalization of $53.97 billion, a P/E ratio of 33.87, a P/E/G ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.32 billion for the quarter. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.